Antiphospholipid syndrome
Template:DiseaseDisorder infobox
|
Antiphospholipid syndrome Microchapters |
|
Differentiating Antiphospholipid syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Antiphospholipid syndrome On the Web |
|
American Roentgen Ray Society Images of Antiphospholipid syndrome |
|
Risk calculators and risk factors for Antiphospholipid syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords:Antiphospholipid antibody syndrome; anticardiolipin syndrome; Hughes syndrome; Lupus anticoagulant
Overview
Pathophysiology & Etiology
|
Antiphospholipid syndrome Microchapters |
|
Differentiating Antiphospholipid syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Antiphospholipid syndrome On the Web |
|
American Roentgen Ray Society Images of Antiphospholipid syndrome |
|
Risk calculators and risk factors for Antiphospholipid syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
Overview
Diagnosis
Antiphospholipid syndrome is tested for in the laboratory using both liquid phase coagulation assays (lupus anticoagulant) and solid phase ELISA assays (anti-cardiolipin antibodies).
Genetic thrombophilia is part of the differential diagnosis of APS and can coexist in some APS patients. Thus genetic thrombophilia screening can consist of:
- Further studies for Factor V Leiden variant and the prothrombin mutation, Factor VIII levels, MTHFR mutation.
- Levels of protein C, free and total protein S, Factor VIII, antithrombin, plasminogen, tissue plasminogen activator (TPA) and plasminogen activator inhibitor-1 (PAI-1)
The testing of antibodies to the possible individual targets of aPL such as β2 Glycoprotein 1 and antiphosphatidyl serine is currently under debate as testing for anticardiolipin appears to be currently sensitive and specific for diagnosis of APS even though cardiolipin is not considered an in vivo target for antiphospholipid antibodies.
Signs and symptoms
The presence of antiphospholipid antibodies (aPL) in the absence of blood clots or pregnancy-related complications does not indicate APS (see below for the diagnosis of APS).
Antiphosphilipid syndrome can cause (arterial/venous) blood clots (in any organ system) or pregnancy-related complications (especially miscarriage in the second or third trimester). In APS patients, the most common venous event is deep vein thrombosis of the lower extremities (blood clot of the deep veins of the legs) and the most common arterial event is stroke.
Other common findings, although not part of the APS Classification Criteria, are thrombocytopenia (low platelet count), heart valve disease, and livedo reticularis (a skin condition). Some patients report headaches and migraines. Antiphospholipid syndrome can rarely mimic multiple sclerosis with an estimated 10% of patients misdiagnosed.
Very few patients with primary APS go on to develop SLE.
Usual Antiphospholipid Antibody Syndrome
- Associated sign and symptoms may include:
- Major Features:
- Venous thrombosis
- Arterial thrombosis
- Thrombocytopenia
- Recurrent fetal loss
- Minor Features:
- Migraine
- Livedo reticularis
- Endocardial valvular vegetations
- Transverse myelopathy
- Chorea
- Leg ulcers
- Major Features:
- Other signs and symptoms include:
- Myocardial Infarction
- Stroke
- Pulmonary embolism
- Amaurosis fugax
- Retinal infarct
- Other visceral infarct
- Peripheral or deep venous occlusion
- Raynaud’s syndrome
- Pulmonary hypertension
- Avascular necrosis
- Recurrent fetal loss (especially in the 2nd or 3rd trimester)
- Pre-eclampsia
- Adrenal insufficiency
- Coomb’s positive hemolysis
- Sudden multi-systemic occlusion (the Catastropic antiphospholipid-antibody syndrome).
Lupus anticoagulant
This is tested for by using a minimum of two coagulation tests that are phospholipid sensitive this is due to the heterogeneous nature of the lupus anticoagulant antibodies. The patient on initial screening will typically have been found to have a prolonged APTT that does not correct in an 80:20 mixture with normal human plasma (50:50 mixes with normal plasma are insensitive to all but the highest antibody levels). The APTT (plus 80:20 mix), dilute Russell's viper venom time (DRVVT), the kaolin clotting time (KCT), dilute thromboplastin time (TDT/DTT) or Prothrombin time (using a lupus sensitive thromboplastin) are the principal tests used for the detection of lupus anticoagulant. These tests must be carried out on a minimum of two occasions at least 6 weeks apart and be positive on each occasion demonstrating persistent positivity to allow a diagnosis of antiphospholipid syndrome. This is to prevent patients with transient positive tests (due to infection etc) being diagnosed as positive.
Distinguishing a lupus antibody from a specific coagulation factor inhibitor (eg: Factor VIII). This is normally achieved by differentiating the effects of a lupus anticoagulant on factor assays from the effects of a specific coagulation factor antibody. The lupus anticoagulant will inhibit all the contact activation pathway antibodies (Factor VIII, Factor IX, Factor XI and Factor XII). Lupus anticoagulant will also rarely cause a factor assay to give a result lower than 35 iudl (35%) where as a specific factor antibody will rarely give a result higher than 10iudl (10%). Monitoring IV anticoagulant therapy by the APTR is compromised due to the effects of the lupus anticoagulant and in these situations is generally best performed using a chromogenic assay based on the inhibition of Factor Xa by Antithrombin in the presence of Heparin.
Anticardiolipin antibodies
These can be detected using an enzyme-linked immunosorbent assay (ELISA) immunological test, which screens for the presence of β2glycoprotein 1 dependent anticardiolipin antibodies (ACA).
A Low platelet count and positivity for antibodies against β2-glycoprotein 1 or phosphatidylserine may also be observed in a positive diagnosis.
Diagnostic Criteria
The diagnosis of APS is made in case of a clinical event (vascular thrombosis or pregnancy event) and repeated positive tests of aPL performed 12 weeks apart (repeat aPL testing is necessary due to the naturally occurring presence of transient low levels of aPL following infections).
The Updated Sapporo APS Classification Criteria are commonly used for APS diagnosis.[1] Based on these criteria, APS diagnosis requires:
- a) Vascular Thrombosis (blood clots) in any organ or tissue or Pregnancy Event (one or more miscarriages after 10th week of gestation, three or more miscarriages before 10th week of gestation, or one or more premature births before 34th week of gestation due to eclampsia) and
- b) Persistenly (12 weeks apart) Positive aPL (lupus anticoagulant test, moderate-to-high titer anticardiolipin antibodies, or moderate-to-high titer β2-glycoprotein-I antibodies).
The International Consensus Statement is commonly used for Catastrophic APS diagnosis.[2] Based on this statement, Definite CAPS diagnosis requires:
- a) Vascular Thrombosis in three or more organs or tissues and
- b) Development of manifestations simultaneously or in less than a week 'and
- c) Evidence of small vessel thrombosis in at least one organ or tissue and
- d) Laboratory confirmation of the presence of aPL.
Some serological tests for syphilis may be positive in aPL-positive patients (aPL bind to the lipids in the test and make it come out positive) although the more specific tests for syphilis that use recombinant antigens will be negative.
Differential Diagnosis
- Hemolytic uremic syndrome-Thrombotic thrombocytopenic purpura (HUS-TTP)
- Disseminated Intravascular Coagulation (DIC)
- Vasculitis
- Embolic disease
- Cryoglobulinemia
- Calciphylaxis
Treatment
The cornerstone of therapy for symptomatic antiphospholipid syndrome hinges on platelet inhibition with or without anticoagulation. Platelet inhibition is often achieved with aspirin, while warfarin and heparin are the mainstays of anticoagulation. Generally there is no indication for primary prophylaxis. Immunosuppression, the use of intravenous immunoglobulin, and plasmapheresis have also been used with modest success.
Anticoagulation
When anticoagulation with warfarin is pursued, some authors recommend a goal INR of 3.0-4.0.[3] However, the current standard of care targets a therapeutic INR of 2.0-3.0 following initial venous thromboembolism, and an INR >3.0 for an arterial event or venous thrombosis refractory to anticoagulation.[4] Khamashta et al in a study of 147 patients with usual antiphopholipid antibody syndrome showed a low rate of recurrent thrombosis in patients with INR >3, with a risk of 7.1% bleeding complications per patient year (a third of which were serious).
Anticoagulation in pregnancy
During pregnancy, low molecular weight heparin and low-dose aspirin are used to avoid warfarin's teratogenicity. Women with recurrent miscarriage are often advised to take aspirin and to start low molecular weight heparin treatment after missing a menstrual cycle.
Platelet inhibition
Aspirin is frequently added to a regimen of chronic anticoagulation, particularly when patients experience recurrent thrombosis despite therapeutic aticoagulation. However data demonstrating additive benefit are lacking.
Immunosuppression
It is not clear that immunosuppression is beneficial, particularly in patients who do not have an underlying autoimmune process. Nevertheless, immunosuppression is often tried in patients who have failed usual anticoagulation. Steroids, for example prednisone 1 mg/kg (or equivalent), has been used with moderate success. Pulse solumedrol IV 1 g/d for 3 days is an alternative regimen. Cyclophosphamide, either oral or pulse IV, has demonstrated modest utility.
Other, more desperate interventions include intravenous immunoglobulin and plasmapheresis. The latter has been shown via case reports to have efficacy in patients who have failed other interventions.
Treatment of catastrophic disease
Optimal treatment has not been clearly defined in this condition. We are limited to data from small case report studies. These patients often display a fulminant course with rapid multiorgan system failure, so multiple interventions are often desperately tried in hopes that the patient might respond to something and survive.
References
- ↑ Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306)
- ↑ Asherson RA, Cervera R, de Groot PG; et al. (2003). "Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines". Lupus. 12 (7): 530–4. PMID 12892393.
- ↑ Horton JD, Bushwick BM (1999). "Warfarin therapy: evolving strategies in anticoagulation". American family physician. 59 (3): 635–646. PMID 10029789.
- ↑ Ruiz-Irastorza G, Hunt BJ, Khamashta MA (2007). "A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies". Arthritis and Rheumatism. 57 (8): 1487–95. doi:10.1002/art.23109. PMID 18050167. Unknown parameter
|month=ignored (help)
Bibliography
- Triona Holden. "Positive Options for Antiphospholipid Antibody Syndrome" ISBN 0-89793-409-1.
- Kay Thackray. Sticky Blood. ISBN 1-898030-77-4. A personal account of dealing with the condition.
Template:Autoantibodies Template:Hematology
de:Anti-Phospholipid-Syndrom id:Sindrom antibodi antifosfolipid nl:Antifosfolipidensyndroom sr:Антифосфолипидни синдром sv:Antifosfolipidsyndrom